ARB 1740

Drug Profile

ARB 1740

Alternative Names: ARB-1740

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Arbutus Biopharma
  • Class Gene therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 03 Aug 2017 Arbutus Biopharma completes a phase II trial in Hepatitis B in USA (Parenteral)
  • 03 Aug 2017 Discontinued - Phase-II for Hepatitis B in USA (Parenteral)
  • 21 Mar 2017 Phase-II clinical trials in Hepatitis B in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top